 |
 |
中國(guo)(guo)上海和美國(guo)(guo)馬薩諸塞州劍橋(qiao)市2022年10月27日 /美通社/ -- 藥明巨(ju)諾（港(gang)交所(suo)代碼：2126），一家(jia)獨立(li)的(de)、專注(zhu)于開(kai)發(fa)(fa)、生(sheng)產及商(shang)業化細胞(bao)(bao)免(mian)疫治療(liao)產品的(de)創(chuang)新型生(sheng)物科技公司，與2seventy bio（納斯達克代碼：TSVT），一家(jia)領(ling)先的(de)免(mian)疫腫瘤(liu)細胞(bao)(bao)治療(liao)公司，今(jin)天宣布(bu)達成戰略合作。雙方將建立(li)細胞(bao)(bao)治療(liao)的(de)轉(zhuan)化及臨床(chuang)開(kai)發(fa)(fa)平(ping)臺，在中國內(nei)地、香港(gang)及澳(ao)門地區加速T細胞(bao)(bao)免(mian)疫治療(liao)產品的(de)開(kai)發(fa)(fa)。
雙方的首要(yao)合(he)作(zuo)將圍繞(rao)2seventy的MAGE-A4 TCR項目，該項目用于治療(liao)實(shi)體(ti)腫(zhong)瘤(liu)，由2seventy與再(zai)生元（Regeneron）合(he)作(zuo)開(kai)發(fa)。MAGE-A4是(shi)癌-睪丸抗原(yuan)(yuan)MAGE家(jia)族的一員，這類抗原(yuan)(yuan)在多種(zhong)實(shi)體(ti)腫(zhong)瘤(liu)中均有表達(da)。該項目旨在開(kai)發(fa)T細胞受(shou)體(ti)（TCR）療(liao)法，用于治療(liao)MAGE-A4陽(yang)性的實(shi)體(ti)腫(zhong)瘤(liu)。
藥明(ming)巨(ju)諾首席醫(yi)學官Mark J. Gilbert博(bo)士表示："我們(men)很(hen)高興(xing)與(yu)2seventy bio攜(xie)手，在(zai)中(zhong)國共同開發MAGE-A4 TCR項目及其他(ta)潛在(zai)的產(chan)品。2seventy bio是(shi)一家業界一流的細(xi)胞治(zhi)療公司，擁有(you)先進(jin)的技術及經驗豐(feng)富的團隊。此次戰略合作將(jiang)進(jin)一步發揮我們(men)包括(kuo)轉化(hua)研究及臨床開發在(zai)內的、世界一流的綜(zong)合能(neng)力，我們(men)期待加速開發更多(duo)具有(you)突破(po)性治(zhi)療價(jia)值的細(xi)胞免疫治(zhi)療產(chan)品，服務更多(duo)中(zhong)國乃至全球的癌癥(zheng)患者(zhe)。"
2seventy bio首席醫(yi)學(xue)官Steve Bernstein表示："此次(ci)合(he)作對于患者(zhe)的(de)真(zhen)正(zheng)價值，在于我(wo)們增強了快速測(ce)試、學(xue)習并(bing)推進我(wo)們創新細胞(bao)治療(liao)項目(mu)的(de)能(neng)力(li)。藥明巨諾對于中(zhong)國患者(zhe)未被滿足(zu)的(de)治療(liao)需求、中(zhong)國的(de)注冊事(shi)務流程(cheng)、以及(ji)臨(lin)床(chuang)開發(fa)路(lu)徑具(ju)有深入(ru)的(de)洞(dong)察。借助此次(ci)合(he)作機會，我(wo)們將(jiang)彼此的(de)獨特優勢經驗相互(hu)結合(he)，建立差異(yi)化的(de)平臺，從而實現我(wo)們的(de)目(mu)標，即讓創新治療(liao)更快地惠及(ji)患者(zhe)。"
根據協議條款(kuan)，2seventy將授權(quan)藥(yao)明(ming)(ming)巨諾在(zai)(zai)(zai)中國內地、香港及(ji)(ji)澳門地區開(kai)展MAGE-A4細胞治療項(xiang)目的權(quan)利，藥(yao)明(ming)(ming)巨諾將負責其(qi)在(zai)(zai)(zai)中國的開(kai)發、生(sheng)產(chan)及(ji)(ji)商(shang)業化，2seventy有權(quan)獲得里程碑付款(kuan)及(ji)(ji)基(ji)于(yu)(yu)產(chan)品收入的特許權(quan)使用(yong)費(fei)。此外，2seventy可(ke)將基(ji)于(yu)(yu)該(gai)合作項(xiang)目而獲得的早期臨床數據用(yong)于(yu)(yu)在(zai)(zai)(zai)其(qi)他地區開(kai)發該(gai)產(chan)品。此次交易的完成尚待取得藥(yao)明(ming)(ming)巨諾股東的批準，并滿足其(qi)他慣例成交條件(jian)。
關于MAGE-A4項目
MAGE-A4是癌-睪丸抗原(yuan)MAGE家族(zu)的(de)(de)一員(yuan)，這類抗原(yuan)在(zai)多(duo)種實體腫瘤中均有表達(da)。我們(men)構造了我們(men)在(zai)與(yu)MediGene的(de)(de)合作中發(fa)(fa)現的(de)(de)一種高(gao)效的(de)(de)TCR，該TCR可識別HLA呈遞的(de)(de)MAGE-A4多(duo)肽，并憑借我們(men)CTBR12 TGF-beta"翻轉"受體技(ji)術進一步增強這些T細胞(bao)的(de)(de)效力(li)，將TGF-beta免疫抑制效應轉化為T細胞(bao)的(de)(de)激活信號。再(zai)生元（Regeneron）和2seventy bio于2018年圍(wei)繞此項目(mu)達(da)成(cheng)合作，目(mu)前(qian)雙方正在(zai)合作開發(fa)(fa)。
關于藥明巨諾
藥明巨諾（港交所代碼：2126）是一家獨立的、創新型的生物科技公司，專注于開發、生產及商業化細胞免疫治療產品，并致力于以創新為先導，成為細胞免疫治療引領者。創建于2016年，藥明巨諾已成功打造了國際領先的細胞免疫治療的綜合性產品開發平臺，以及涵蓋血液及實體腫瘤的細胞免疫治療產品管線。藥明巨諾致力于以突破性、高品質的細胞免疫治療產品給中國乃至全球患者帶來治愈的希望，并引領中國細胞免疫治療產業的健康規范發展。欲了解更多詳情，請訪問：。
關于2seventy bio
Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape.
With a deep understanding of the human body's immune response to tumor cells and how to translate cell therapies into practice, we're applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to "think" smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our "why" and keeping our people and culture top of mind every day.
For more information, visit .
Follow 2seventy bio on social media: and .
2seventy bio is a trademark of 2seventy bio, Inc.
藥明巨諾前瞻性聲明
本發(fa)布(bu)(bu)所(suo)包含(han)的(de)(de)前瞻(zhan)性聲(sheng)明(ming)是基于管理層現有(you)的(de)(de)期(qi)望和(he)信(xin)心，會存(cun)在一定的(de)(de)不確定性或(huo)風(feng)險(xian)從而導(dao)致實際結果在實質上(shang)與(yu)所(suo)描(miao)述的(de)(de)有(you)所(suo)區別。顯著的(de)(de)風(feng)險(xian)和(he)不確定性，可能包括了以下涉及的(de)(de)內(nei)容，以及在公(gong)(gong)司(si)(si)提(ti)交(jiao)給香港交(jiao)易所(suo)（HKEX）的(de)(de)報告(gao)中予以更為全面的(de)(de)描(miao)述。除非(fei)另有(you)注明(ming)，公(gong)(gong)司(si)(si)提(ti)供截至發(fa)布(bu)(bu)日(ri)(ri)期(qi)當日(ri)(ri)的(de)(de)信(xin)息，并且明(ming)確無義務更新相關事項及其所(suo)含(han)內(nei)容或(huo)提(ti)供任(ren)何解釋。具(ju)體(ti)內(nei)容，詳見(jian)公(gong)(gong)司(si)(si)官網：。
Cautionary Note Regarding Forward-Looking Statements of 2seventy bio
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: statements about our plans, strategies, timelines and expectations with respect to the development, manufacture or sale of our product candidates, including the results and expected timing of ongoing and planned clinical trials for our product candidates in China and the speed with which we can bring those candidates into clinical trials; statements about the efficacy and perceived therapeutic benefits of our product candidates and the potential indications, market opportunities and demand therefor; statements about the strategic plans for 2seventy bio and potential corporate development opportunities; statements regarding the company's financial condition, and other future financial results; and statements about our ability to execute our strategic priorities. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation; the risk that our plans with respect to the preclinical and clinical development and regulatory approval of our product candidates may not be successfully achieved on the planned timeline, or at all. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2021, as supplemented and/or modified by our most recent Quarterly Report on Form 10-Q and any other filings that we have made or will make with the Securities and Exchange Commission in the future. All information in this press release is as of the date of the release, and 2seventy bio undertakes no duty to update this information unless required by law.
藥明巨諾
投資者問詢：
媒體問詢：
2seventy bio
投資者問詢：
Elizabeth Pingpank, +1 860-463-0469
媒體問詢：
Morgan Adams, +1 774-313-9852
